Comparative Risk for Harms of Second-Generation Antidepressants
- 1 January 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Drug Safety
- Vol. 31 (10), 851-865
- https://doi.org/10.2165/00002018-200831100-00004
Abstract
No abstract availableKeywords
This publication has 124 references indexed in Scilit:
- Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort studyBMJ, 2006
- A randomized, double-blind, 24‐week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorderCurrent Medical Research and Opinion, 2005
- Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorderInternational Clinical Psychopharmacology, 2005
- Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control studyBMJ, 2005
- Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double‐blind, randomised 6‐month comparative trial with citalopramInternational Journal of Geriatric Psychiatry, 2004
- A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetineClinical Therapeutics, 2001
- Clinical and Economic Comparison of Sertraline and Fluoxetine in the Treatment of DepressionPharmacoEconomics, 1998
- A Comparison of Fluvoxamine and Fluoxetine in the Treatment of Major DepressionJournal of Clinical Psychopharmacology, 1996
- Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatientsInternational Clinical Psychopharmacology, 1996
- A Double-Blind, Randomized, Fluoxetine-Controlled, Multicenter Study of Paroxetine in the Treatment of DepressionJournal of Clinical Psychopharmacology, 1993